VERACIS® is a development and CLIA compliant laboratory that is a wholly owned subsidiary of ImmunArray USA and located in Richmond, Va.
VERACIS® collaborates with pharmaceutical and diagnostic companies to develop iCHIP® and ELISA-based diagnostic products to support clinicians in the fields of autoimmune and neurodegenerative disease diagnosis. Ultimately this includes companion diagnostics for therapeutic drugs and biomarker panels for medical devices used in patient management. VERACIS® also provides ImmunArray with the ability to sell laboratory developed tests directly to physicians.
Launched in Q4 of 2015 to rule-out a diagnosis of Systemic Lupus Erythematous (SLE), the SLE-key®RuleOut test is our first commercial product and used by rheumatologists nationwide. The SLE-key®RuleOut test is based on the iCHIP® technology platform in-licensed from the Weizmann Institute of Science.
Products in development include:
- SLE Disease Activity Monitoring test
- Traumatic Brain Injury (TBI) based on ELISA biomarker panels and iCHIP® microarrays to help physicians provide long-term monitoring of the effectiveness of patient treatment. Our TBI program is based on a series of biomarkers in-licensed from Johns Hopkins University and products developed by the company.
- Multiple Sclerosis based on iCHIP® microarrays and IP licensed from Brigham and Women’s Hospital, and Harvard Medical School.
- Immune-Oncology based on iCHIP® microarrays and using proprietary oligonucleotides developed by the company.